Zytiga

Impact of Prior Abiraterone Acetate (Zytiga) on Subsequent Activity of Docetaxel (Chemotherapy) in Men with Metastatic Castration-Resistant Prostate Cancer

The explosion of new therapies for men with metastatic castration resistant prostate cancer (mCRPC) raises serious questions about the optimal sequencing of these new treatments as well as whether cross-resistance occurs between these drugs. It was recently reported that chemotherapy with docetaxel (D) is not effective in in men who did not have a ? [...]

By Malecare|2017-10-19T10:48:29-04:00April 1st, 2014|abiraterone acetate, Advanced Prostate Cancer, Chemo Therapy, Chemo Therapy Failure, Cross Resistance, Drugs & Treatments, Uncategorized, Understanding APC, Zytiga|0 Comments

More Issues Raised About Cross-Resistance Between Abiraterone and Enzalutamide

Some of my posts over the last week or two have discussed the issue of the development of cross-resistance of two of our newest treatments for advanced prostate cancer. These drugs are abiraterone (Zytiga) and enzalutamide (Xtandi). Currently, both of them are approved for use after a man has failed chemotherapy with docetaxel. In addition, [...]

By Malecare|2017-10-19T10:48:30-04:00March 13th, 2014|abiraterone acetate, Advanced Prostate Cancer, Cross Resistance, enzalutamide, Uncategorized, Understanding APC, Xtandi, Zytiga|0 Comments

There is Some Cross Resistance Developed Between Both the First Use of Zytiga and the First Use of Xtandi

On March 4, 2014 I wrote a post “Castrate Resistant Prostate Cancer- What to Do Next” (www.advancedprostatecancer.net/?p=4425). The basic theme of the post was about how difficult it is to know how to sequence the new drugs we have to treat advanced prostate cancer (metastatic castrate resistant prostate cancer aka mCRPC). In the post I [...]

By Malecare|2017-10-19T10:48:32-04:00March 7th, 2014|abiraterone acetate, Advanced Prostate Cancer, Combination Therapy, Cross Resistance, Drugs & Treatments, enzalutamide, Uncategorized, Understanding APC, Xtandi, Zytiga|0 Comments

Castrate Resistant Prostate Cancer- What To Do Next?

Confusion, confusion and more confusion, that is how I would describe the current decision making process for a man with prostate cancer that has become newly castrate resistant. Just a few years ago the decision tree was clear, castrate resistant, immediately on to chemotherapy with docetaxel. Today, in this treatment space, we have a number [...]

By Malecare|2020-02-04T10:11:58-05:00March 4th, 2014|abiraterone acetate, Advanced Prostate Cancer, Drugs & Treatments, enzalutamide, General Information, Prostvac, Provenge, Understanding APC, Xtandi, Zytiga|1 Comment

Can Zytiga Be Used In Men Previously Treated With Ketoconazole: A Prospective Phase II Study

Some men with advanced prostate cancer have been given the antifungal treatment Ketoconazole (Keto) as a second line hormone treatment. Like Keto, this newer hormone treatment that is now available, Abiraterone acetate (AA) (Zytiga) works by inhibiting CYP17, the rate-limiting enzyme in androgen biosynthesis. The question being asked, if Keto has failed ,given its similar [...]

By Malecare|2017-10-19T10:48:35-04:00February 14th, 2014|abiraterone acetate, Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, ketoconazole, Uncategorized, Zytiga|0 Comments

Xtandi Shows Activity in Men with Prostate Cancer Resistant to Chemotherapy and Zytiga

Since its FDA approval in 2011 FDA abiraterone (Zytiga) has supplanted docetaxel (chemotherapy), other than perhaps Provenge, as preferred first-line treatment for metastatic castrate-resistant prostate cancer. August 2012 saw the FDA approval of enzalutamide (Xtandi) for the treatment of castrate-resistant prostate cancer after chemotherapy. Researchers performed a retrospective chart review at a large medical oncology [...]

By Malecare|2017-10-19T10:48:35-04:00February 13th, 2014|abiraterone acetate, Advanced Prostate Cancer, Chemo Therapy, Chemo Therapy Failure, Drugs & Treatments, enzalutamide, Provenge, Uncategorized, Xtandi, Zytiga|0 Comments

Zytiga in Québec, Radium-223 in England & Lets Change Our Antiquated Approval Nonsense

Men with metastatic castration-resistant prostate cancer (mCRPC) in Québec, Canada now have access to Zytiga (abiraterone acetate) prior to having chemotherapy. Effective February 3, 2014, the province has added ZYTIGA to the public drug formulary for the treatment of mCRPC in men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT). [...]

By Malecare|2014-02-06T22:31:17-05:00February 6th, 2014|abiraterone acetate, Advanced Prostate Cancer, Advocacy, Alpharadin (radium-223), Drugs & Treatments, Early/Expanded Access Programs, General Information, radiopharmaceuticals, Uncategorized, United Kingdom - England, Northern Ireland, Scotland & Wales, Xgeva, Xofigo, Zytiga|2 Comments

Correcting the NICE Guidance for Xtandi – It is worse for Men with Progressive Advanced Prostate Cancer

After a great deal of confusion and what turned out to be an error on my part I wish to let you know that the NICE (The U.K.’s National Institute for Health and Care Excellence) Guidance I shared on the blog on January 28, 2014 (http://advancedprostatecancer.net/?p=4360 ) about enzalutamide (Xtandi) was not accurate. In my [...]

By Malecare|2020-02-04T08:50:07-05:00February 5th, 2014|abiraterone acetate, Advanced Prostate Cancer, Advocacy, Cabazitaxel, Chemo Therapy Failure, Drugs & Treatments, Enzalutamide (MDV-3100), Politics of Cancer, Uncategorized, Xtandi, Zytiga|2 Comments

NICE Changes Its Mind & Reverses Its Prior Decision on the Use of Xtandi in the UK!

Live in the UK and have advanced prostate cancer? If you do then be prepared to have economics over-ride your legitimate health concerns. The U.K.'s National Institute for Health and Care Excellence (NICE) makes no bones about what is more important, money or men’s health. NICE initially did not approve Zytiga, however when Johnson & [...]

By Malecare|2017-10-19T10:49:03-04:00January 28th, 2014|abiraterone acetate, Advanced Prostate Cancer, Advocacy, Drugs & Treatments, Enzalutamide (MDV-3100), Fail First Therapy, Financial, General Information, Politics of Cancer, step therapy, Uncategorized, United Kingdom - England, Northern Ireland, Scotland & Wales, Xtandi, Zytiga|0 Comments

A Statistical Nightmare – Comparing the Efficacy of Zytiga & Xtandi In the Pre-Chemo Setting

Based on the assumption that Enzalutamide (Xtandi) is approved for use in men with castrate resistant metastatic prostate cancer (advanced prostate cancer or mCRPC) who have not had prior chemotherapy, pretty much a foregone conclusion based on the extraordinary phase III Prevail Trial results, including a statistically significant survival advantage of 2.2 months with a [...]

By Malecare|2017-10-19T10:49:05-04:00January 23rd, 2014|abiraterone acetate, Advanced Prostate Cancer, Drugs & Treatments, enzalutamide, Enzalutamide (MDV-3100), MDV3100, Uncategorized, Understanding APC, Xtandi, Zytiga|1 Comment